Cardiac-Specific Overexpression of Caveolin-1 in Rats With Ischemic Cardiomyopathy Improves Arrhythmogenicity and Cardiac Remodelling

Wu, Shu-jie; He, Rui-lin; Zhang, Lin; Yu, Xiao-yu; Jiang, Yongchao; Guan, Xuan; Chen, Qiao-ying; Ren, Fangfang; Xie, Zuo-yi; Wu, Lianpin; Li, Lei

doi:10.1016/j.cjca.2022.10.005

Cited by 2 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MG53 inhibits the IGF-induced IRS-1/PI (3)K/Akt pathway, which is the best-characterized mechanism in cardiac and skeletal muscle myogenesis, through the ubiquitin-dependent degradation of IRS-1 ( 125 , 139 , 146 , 147 ). Caveolin-1 plays an antifibrotic role in multiple organs and reduces cardiac fibrosis by repressing the TGF-β/Smad2 pathway ( 148 , 149 ). MG53 can inhibit the expression of caveolin-1, thereby promoting TGF-β1/SMAD2-induced myocardial fibrosis ( 150 ).…”

Section: Potential Adverse Effects Of Mg53 On Cancer Treatmentmentioning

confidence: 99%

Is MG53 a potential therapeutic target for cancer?

Du,

Li,

2023

Front. Endocrinol.

View full text Add to dashboard Cite

Cancer treatment still encounters challenges, such as side effects and drug resistance. The tripartite-motif (TRIM) protein family is widely involved in regulation of the occurrence, development, and drug resistance of tumors. MG53, a member of the TRIM protein family, shows strong potential in cancer therapy, primarily due to its E3 ubiquitin ligase properties. The classic membrane repair function and anti-inflammatory capacity of MG53 may also be beneficial for cancer prevention and treatment. However, MG53 appears to be a key regulatory factor in impaired glucose metabolism and a negative regulatory mechanism in muscle regeneration that may have a negative effect on cancer treatment. Developing MG53 mutants that balance the pros and cons may be the key to solving the problem. This article aims to summarize the role and mechanism of MG53 in the occurrence, progression, and invasion of cancer, focusing on the potential impact of the biological function of MG53 on cancer therapy.

show abstract

Section: Potential Adverse Effects Of Mg53 On Cancer Treatmentmentioning

confidence: 99%

Is MG53 a potential therapeutic target for cancer?

Du,

Li,

2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Atrial fibroblasts are more prone to fibrosis compared to ventral fibroblasts, making the inhibition of the fibrotic phenotype of atrial fibroblasts crucial in treating atrial fibrillation. 63 Recent studies 64 have linked the niche protein Caveolin-1(CAV1) to myocardial fibrosis, with CAV1 knockout mice exhibiting structural changes in the ventricle and interstitial fibrosis. Zhang et al 65 demonstrated that MG53 can regulate TGF-β1/SMAD2 signalling pathway-induced atrial fibrosis through a molecular target of CAV1.…”

Section: The Dual Impact Of Mg53 On Cardiac Health: Positive and Nega...mentioning

confidence: 99%

Advances in the Study of MG53 in Cardiovascular Disease

Liu,

Zhao,

et al. 2023

IJGM

View full text Add to dashboard Cite

Cardiovascular diseases represent a global health crisis, and understanding the intricate molecular mechanisms underlying cardiac pathology is crucial for developing effective diagnostic and therapeutic strategies. Mitsugumin-53 (MG53) plays a pivotal role in cell membrane repair, has emerged as a multifaceted player in cardiovascular health. MG53, also known as TRIM72, is primarily expressed in cardiac and skeletal muscle and actively participates in membrane repair processes essential for maintaining cardiomyocyte viability. It promotes k-ion currents, ensuring action potential integrity, and actively engages in repairing myocardial and mitochondrial membranes, preserving cardiac function in the face of oxidative stress. This study discusses the dual impact of MG53 on cardiac health, highlighting its cardioprotective role during ischemia/reperfusion injury, its modulation of cardiac arrhythmias, and its influence on cardiomyopathy. MG53’s regulation of metabolic pathways, such as lipid metabolism, underlines its role in diabetic cardiomyopathy, while its potential to mitigate the effects of various cardiac disorders, including those induced by antipsychotic medications and alcohol consumption, warrants further exploration. Furthermore, we examine MG53’s diagnostic potential as a biomarker for cardiac injury. Research has shown that MG53 levels correlate with cardiomyocyte damage and may predict major adverse cardiovascular events, highlighting its value as a biomarker. Additionally, exogenous recombinant human MG53 (rhMG53) emerges as a promising therapeutic option, demonstrating its ability to reduce infarct size, inhibit apoptosis, and attenuate fibrotic responses. In summary, MG53’s diagnostic and therapeutic potential in cardiovascular diseases presents an exciting avenue for improved patient care and outcomes.

show abstract

Cardiac-Specific Overexpression of Caveolin-1 in Rats With Ischemic Cardiomyopathy Improves Arrhythmogenicity and Cardiac Remodelling

Cited by 2 publications

References 42 publications

Is MG53 a potential therapeutic target for cancer?

Is MG53 a potential therapeutic target for cancer?

Advances in the Study of MG53 in Cardiovascular Disease

Contact Info

Product

Resources

About